Blood cancer drug from GSK fails main goal of trial
GSK has released a statement on the failure of Blenrep in achieving the main goals of a late-stage study for the blood cancer therapeutic, raising concerns of regulatory approval being rescinded.
Blenrep, GSK’s blood cancer drug, has failed the main of its late-stage study designed to demonstrate the primary endpoint of ‘progression-free survival’ - the period in which a patient with relapsed or refractory multiple myeloma lives with the disease without worsening after treatment.
An antibody–drug conjugate, Blenrep joins a number of engineered antibodies with the ability to bind to tumour cells and release cell-killing chemicals. The drug was given accelerated approval by US authorities in 2020 for the indication of relapsed or refractory multiple myeloma in patients who had received a minimum of four prior therapies. In this late-stage trial, Blenrep was compared with a combination of pomalidomide and dexamethasone. Developed by Celgene, now a part of Bristol-Myers Squibb, pomalidomide was approved in 2013 for the treatment of multiple myeloma. From the trial, the data may result in Blenrep’s existing approvals being rescinded.
J.P. Morgan analysts commented that “Overall, with this data calling into question Blenrep’s approvability in the existing setting and the chances of success in earlier treatment lines, we therefore expect the market to price in a risk that Blenrep’s approval is rescinded.”
Additional trials of Blenrep are currently continuing as planned while GSK states that data from this particular trial will be shared with health authorities.
Source: GSK's blood cancer drug fails main goal of trial, shares fall | Reuters
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance